⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16054017 | 0.98 | PNMT (0.44) | — | |
| SCHEMBL3533710 | 0.88 | DRD2 (0.39) | — | |
| SCHEMBL3725694 | 0.86 | DRD2 (0.38) | — | |
| SCHEMBL550241 | 0.85 | DRD2 (0.46) | — | |
| SCHEMBL9500822 | 0.83 | PNMT (0.41) | — | |
| SCHEMBL397802 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL550220 | 0.83 | DRD2 (0.44) | — | |
| Hydrochloric Acid SCHEMBL22395725 | 0.82 | DRD2 (0.40) | — | |
| Hydrochloric Acid SCHEMBL12485568 | 0.82 | DRD2 (0.40) | — | |
| SCHEMBL951473 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132480-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC. | 2024-04-25 | — | — | US | claimed |
| CN-111491918-B | Aryl and heteroaryl substituted indole compounds | 百时美施贵宝公司 | 2023-10-24 | — | — | CN | claimed |
| US-20220289753-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-09-15 | — | — | US | claimed |
| WO-2022150574-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | CORNELL UNIVERSITY (US) | 2022-07-14 | — | — | WO | claimed |
| CN-114728935-A | SHP2 inhibitor | IRBM股份公司 | 2022-07-08 | — | — | CN | claimed |
| EP-4010335-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-06-15 | — | — | EP | claimed |
| WO-2021028362-A1 | SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2021-02-18 | — | — | WO | claimed |
| EP-3772513-A1 | SHP2 INHIBITORS | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening (IT) | 2021-02-10 | — | — | EP | claimed |
| US-20100292188-A1 | Compounds Comprising A Cyclobutoxy Group | UCB PHARMA S.A. (BE) | 2010-11-18 | — | — | US | claimed |
| EP-2238144-A1 | COMPOUNDS COMPRISING A CYCLOBUTOXY GROUP | UCB Pharma, S.A. (BE) | 2010-10-13 | — | — | EP | claimed |
| WO-2009092764-A1 | COMPOUNDS COMPRISING A CYCLOBUTOXY GROUP | UCB PHARMA, S.A. (BE) | 2009-07-30 | — | — | WO | claimed |
| WO-2026099510-A1 | RESILIENT MARKER COMPOUNDS | MINTON, TREHARNE & DAVIES LIMITED (GB) | 2026-05-15 | — | — | WO | disclosed |
| WO-2026087753-A1 | PROCESS FOR REDUCING A NITROGEN-CONTAINING FUNCTIONAL GROUP | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2026-04-30 | — | — | WO | disclosed |
| EP-4733294-A1 | NOVEL PROCESS | Oxford University Innovation Limited (GB) | 2026-04-29 | — | — | EP | disclosed |
| US-20260085077-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-03-26 | — | — | US | disclosed |
| EP-2049548-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB Pharma, S.A. (BE) | 2009-04-22 | — | — | EP | disclosed |
| EP-2019094-A1 | HETEROCYCLIC TYPE CINNAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2009-01-28 | — | — | EP | disclosed |
| WO-2008012010-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB PHARMA, S.A. (BE) | 2008-01-31 | — | — | WO | disclosed |
| EP-1287018-A2 | THROMBIN INHIBITORS | Lek Pharmaceutical and Chemical Co. D.D. (SI) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001085760-A1 | THROMBIN INHIBITORS | LEK PHARMACEUTICAL & CHEMICAL CO. DD (SI) | 2001-11-15 | — | — | WO | disclosed |